Suzhou Zelgen Biopharmaceuticals Co., Ltd.
688266
Peringkat dalam Saham
#4064
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries,... Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate and high-risk myelofibrosis. It also develops drug candidates in the NDA, Phase III, or registration clinical trial stages, such as gecacitinib hydrochloride tablets for severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis, ruxolitinib-intolerant and relapsed/refractory myelofibrosis, moderate to severe plaque psoriasiste, idiopathic pulmonary fibrosis, severe alopecia areata, nonsegmental vitiligo, and myelofibrosis; and recombinant human thyroid-stimulating hormone for injection. In addition, the company is developing drug candidates in Phase I/II clinical trial stages consisting of donafenib tablets for liver cancer and anti-tumor immunotherapy; gecacitinib hydrochloride cream for mild to moderate alopecia areata and atopic dermatitis, and nonsegmental vitiligo; ZG19018 and ZG2001 tablets for KRAS G12C and KRAS mutation late-stage solid tumors; and ZG005, ZGGS18, ZGGS15, ZG0895, and ZG006 powders for injections for late-stage solid tumors. Further, it develops pre-clinical drug candidates, including ZG1905 for topical bleeding; and ZGGS001 and GS11 powders for injections for late-stage tumors. The company’s products are used in multiple therapeutic areas, such as tumors, bleeding and blood diseases, and immune inflammatory diseases. Suzhou Zelgen Biopharmaceuticals Co., Ltd. was founded in 2009 and is based in Kunshan, the People's Republic of China.
Harga Saham
$14.90
Kapitalisasi Pasar
$3.94B
Perubahan (1 hari)
-2.98%
Perubahan (1 tahun)
2.29%
Negara
CN
Perdagangan Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266)
Kategori
Healthcare
Margin Operasi untuk Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266)
Margin Operasi per October 2026 TTM: 31.80%
Menurut laporan keuangan dan harga saham terbaru dari Suzhou Zelgen Biopharmaceuticals Co., Ltd., margin operasi saat ini (TTM) adalah 31.80%. Pada akhir 2024, margin operasi perusahaan adalah -29.09%.
Riwayat margin operasi untuk Suzhou Zelgen Biopharmaceuticals Co., Ltd. dari 2016 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Mengubah |
|---|---|---|
| 2026 (TTM) | 31.80% | -204.78% |
| 2025 | -30.35% | 4.33% |
| 2024 | -29.09% | -62.25% |
| 2023 | -77.06% | -52.02% |
| 2022 | -160.62% | -33.39% |
| 2021 | -241.14% | -78.12% |
| 2020 | -1,102.02% | 0.00% |
| 2019 | 0.00% | -100.00% |
| 2018 | -33,760.07% | 0.00% |
| 2017 | 0.00% | -100.00% |
| 2016 | -66,705.10% | 0.00% |
Margin Operasi untuk perusahaan sejenis atau pesaing
| Perusahaan | Margin Operasi | Perbedaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -98.79% |
US
|
|
| -149.01% | -104.69% |
US
|
|
| 25.57% | -99.20% |
AU
|
|
| 28.81% | -99.09% |
NL
|
|
| 31.23% | -99.02% |
BE
|
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.